Voyager Q1 net loss $27.9M, cash $172M into 2028; VY1706 tau gene therapy on track for H2 dosing

Voyager Therapeutics, Inc.

2026-Q1 EPS reported -$0.47 revenue$2,593,000

Net loss $27.9M (Q1 2026) vs $31.0M (Q1 2025); revenue $2.6M down from $6.5M due to lower collaboration revenue.
Cash, equivalents and marketable securities $171.7M; runway expected into 2028.
VY1706 tau silencing gene therapy: IND-enabling GLP tox completed; FDA IND on track for Q2, first-in-human dosing H2 2026.
VY7523 anti-tau antibody: tau PET imaging efficacy data from MAD trial expected H2 2026.
Neurocrine's NBIB-'223 for Friedreich's ataxia: GLP tox completed, FDA orphan drug designation; clinical trial H2 2026 pending IND.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Voyager Therapeutics, Inc. reported first quarter 2026 results: revenue $2.6 million, net income $27.9 million.

Period: first quarter 2026
Revenue: $2.6 million
Net income: $27.9 million
Result: reported results

Exact text from the filing

Collaboration revenue was $2.6 million for the three months ended March 31, 2026, compared to $6.5 million for the first quarter of 2025.

View on SEC.gov

Browse all earnings releases →

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-057115

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.